Enanta Pharmaceuticals Inc (NASDAQ:ENTA)

101.00
Delayed Data
As of 10:35am ET
 -1.49 / -1.46%
Today’s Change
29.46
Today|||52-Week Range
108.00
+72.11%
Year-to-Date
AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
May 21 / Zacks.com - Paid Partner Content
Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down
May 11 / Zacks.com - Paid Partner Content
Should Guggenheim S&P SmallCap 600 Pure Growth ETF (RZG) Be on Your Investing Radar?
May 21 / Zacks.com - Paid Partner Content
Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down
May 11 / Zacks.com - Paid Partner Content
Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study
May 18 / Zacks.com - Paid Partner Content
Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss
May 11 / Zacks.com - Paid Partner Content
Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion
May 17 / Zacks.com - Paid Partner Content
Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up
May 11 / Zacks.com - Paid Partner Content
Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study
May 16 / Zacks.com - Paid Partner Content
Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses
May 10 / Zacks.com - Paid Partner Content
Roche's Actemra Gets FDA Nod for Subcutaneous Formulation
May 15 / Zacks.com - Paid Partner Content
Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus
May 10 / Zacks.com - Paid Partner Content
Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?
May 14 / Zacks.com - Paid Partner Content
VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters
May 10 / Zacks.com - Paid Partner Content
Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat
May 11 / Zacks.com - Paid Partner Content